Avastin for Post-photocoagulation Macular Edema
Phase 4
Withdrawn
- Conditions
- Macular Edema
- Interventions
- Procedure: Panretinal Photocoagulation
- Registration Number
- NCT00801866
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Brief Summary
to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with Proliferative retinopathy or severe non-proliferative retinopathy
- BCVA of 20/63 or better (56 ETDRS letters
- No history of Macular Edema
- Central Retinal Thickness of 250mics or more
Exclusion Criteria
- Previous treatment.
- Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy
- Media opacities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Bevacizumab Panretinal Photocoagulation + Bevacizumab Group 2 Panretinal Photocoagulation Panretinal Photocoagulation
- Primary Outcome Measures
Name Time Method Best Corrected Visual Acuity
- Secondary Outcome Measures
Name Time Method Central Retinal Thickness.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bevacizumab's efficacy in preventing post-photocoagulation macular edema in diabetic retinopathy?
How does intravitreal bevacizumab compare to standard panretinal photocoagulation in managing macular thickening in NPDR and PDR patients?
Which biomarkers are associated with response prediction to intravitreal bevacizumab in post-photocoagulation macular edema?
What are the potential adverse events of intravitreal bevacizumab in diabetic retinopathy and how are they managed?
Are there combination therapies or alternative anti-VEGF agents that enhance outcomes for post-photocoagulation macular edema compared to bevacizumab?
Trial Locations
- Locations (1)
Asociación para Evitar la Ceguera en México
🇲🇽Mexico, DF, Mexico
Asociación para Evitar la Ceguera en México🇲🇽Mexico, DF, Mexico